We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M Turnover 17.65%
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
+15.27%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$878M
AUM Growth
-$262M
Cap. Flow
-$297M
Cap. Flow %
-33.85%
Top 10 Hldgs %
94.53%
Holding
27
New
2
Increased
–
Reduced
–
Closed
3
Avg Time Held
0.2 years
Top 10 Avg Time Held
0.2 years
Top 20 Avg Time Held
0.2 years

Top Buys

Rank Stock Value
1
XNCR icon
Xencor
XNCR
+$28.4M
2
NNOX icon
Nano X Imaging
NNOX
+$3.99M

Top Sells

Rank Stock Value
1
ILMN icon
Illumina
ILMN
+$329M
2
NPCE icon
Neuropace
NPCE
+$879K
3
ZY
Zymergen Inc. Common Stock
ZY
+$218K

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Technology 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARWR icon
1
Arrowhead Research
ARWR
$8.25B
$216M 24.61%
3,260,869
– –
2021 Q3
1 quarter
FATE icon
2
Fate Therapeutics
FATE
$232M
$198M 22.51%
3,379,064
– –
2021 Q3
1 quarter
PTGX icon
3
Protagonist Therapeutics
PTGX
$8.82B
$83.8M 9.54%
2,449,183
– –
2021 Q3
1 quarter
LEGN icon
4
Legend Biotech
LEGN
$3.7B
$75.9M 8.64%
1,629,173
– –
2021 Q3
1 quarter
HLTH icon
5
DELISTED
Cue Health Inc. Common Stock
HLTH
$74.4M 8.47%
5,548,864
– –
2021 Q3
1 quarter
MGTX icon
6
MeiraGTx Holdings
MGTX
$904M
$68.8M 7.83%
2,898,550
– –
2021 Q3
1 quarter
CVRX icon
7
CVRx
CVRX
$35.7M
$42.8M 4.87%
3,495,575
– –
2021 Q3
1 quarter
XNCR icon
8
Xencor
XNCR
$1.74B
$30M 3.42%
+748,062
New +$28.4M
2021 Q4
0 quarters
PRCT icon
9
Procept Biorobotics
PRCT
$1B
$25.5M 2.9%
1,018,478
– –
2021 Q3
1 quarter
FUSN icon
10
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$15.3M 1.74%
3,670,516
– –
2021 Q3
1 quarter
ACET icon
11
Adicet Bio
ACET
$45.8M
$12.7M 1.45%
45,559
– –
2021 Q3
1 quarter
VOR icon
12
Vor Biopharma
VOR
$1.11B
$12.5M 1.42%
53,733
– –
2021 Q3
1 quarter
PNT
13
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$5.6M 0.64%
1,000,000
– –
2021 Q3
1 quarter
PHAS
14
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$4.19M 0.48%
1,607,044
– –
2021 Q3
1 quarter
HLSQ
15
Tessera Defense and Homeland Security Inc.
HLSQ
$2.15M
$3.41M 0.39%
1,123
– –
2021 Q3
1 quarter
SLGC
16
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$3.27M 0.37%
281,052
– –
2021 Q3
1 quarter
NNOX icon
17
Nano X Imaging
NNOX
$40.1M
$2.8M 0.32%
+192,429
New +$3.99M
2021 Q4
0 quarters
ALDX icon
18
Aldeyra Therapeutics
ALDX
$47.7M
$1.58M 0.18%
394,834
– –
2021 Q3
1 quarter
CSLT
19
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$1.25M 0.14%
811,295
– –
2021 Q3
1 quarter
TCON
20
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$233K 0.03%
4,200
– –
2021 Q3
1 quarter
LUNG icon
21
Pulmonx
LUNG
$76.4M
$181K 0.02%
5,639
– –
2021 Q3
1 quarter
SENS icon
22
Senseonics Holdings Inc
SENS
$428M
$146K 0.02%
2,731
– –
2021 Q3
1 quarter
CALC icon
23
CalciMedica
CALC
$7.31M
$91K 0.01%
708
– –
2021 Q3
1 quarter
GYRE icon
24
Gyre Therapeutics
GYRE
$686M
$61K 0.01%
8,927
– –
2021 Q3
1 quarter
ILMN icon
25
Illumina
ILMN
$41B
– –
-832,855
Closed -$329M –
1
2

Similar funds

SEM
Suncoast Equity Management Tampa, Florida $798M AUM 14.62% 1-Year Est. Return
TI
TrueMark Investments Chicago, Illinois $798M AUM 25.52% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $798M AUM 18.61% 1-Year Est. Return
QCMNJ
Quantum Capital Management (New Jersey) Northfield, New Jersey $798M AUM 8.86% 1-Year Est. Return
LOPW
Live Oak Private Wealth Wilmington, North Carolina $800M AUM 24.59% 1-Year Est. Return
HW
HORAN Wealth Cincinnati, Ohio $800M AUM 23.65% 1-Year Est. Return
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return

Johnson & Johnson's Q4 2021 Portfolio in Review

As of Q4 2021, Johnson & Johnson held 27 positions worth $878M, down 23% from $1.14B the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Johnson & Johnson withdrew a net $297M in Q4 2021, closing 3 positions. Its most notable exit was Illumina, an estimated $329M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology.

Against the trend, Johnson & Johnson opened a new position in Xencor worth $30M.

  • Johnson & Johnson's largest Q4 2021 buy was Xencor: 748,062 shares worth $30M.
  • Johnson & Johnson fully exited Illumina in Q4 2021, selling an estimated $329M.
  • Johnson & Johnson's ten largest holdings make up 95% of its $878M portfolio in Q4 2021.
  • Johnson & Johnson opened 2 new positions and closed 3 in Q4 2021.
  • Johnson & Johnson's portfolio value fell 23% quarter-over-quarter to $878M.

Based on Johnson & Johnson's 13F filing for Q4 2021, filed 14 Feb 2022.